Senhwa Biosciences Signs AI-Driven Drug Development Partnership with CellType

Senhwa Biosciences has signed a major strategic Memorandum of Understanding with Y Combinator-backed biotech company CellType to advance the development of its oncology candidate Silmitasertib (CX-4945), announced in a press release.

The collaboration will integrate CellType’s AI platform to accelerate clinical development and global commercialization of CX-4945. The technology, originally developed at Yale University in collaboration with Google DeepMind, identified a new immune-modulatory mechanism for the compound. This research showed that CX-4945 may enhance immune activation, improve tumor antigen presentation, and convert non-responsive tumors into responsive ones.

Under the agreement, Senhwa and CellType will run a six-month pilot program focusing on indication expansion, biomarker discovery, and evaluation of combination therapies in immuno-oncology. The framework also includes plans to establish an AI-driven translational validation system.

CellType will use CX-4945 as a flagship case to demonstrate its AI platform’s capacity to reduce R&D risk and enhance therapeutic value. The partnership also leaves room for potential future collaborations, including joint ventures or co-development arrangements.